↓ Skip to main content

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

Overview of attention for article published in Clinical Cancer Research, September 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
1 news outlet
patent
38 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
163 Dimensions

Readers on

mendeley
116 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
Published in
Clinical Cancer Research, September 2009
DOI 10.1158/1078-0432.ccr-09-0068
Pubmed ID
Authors

Chrystelle Brignone, Bernard Escudier, Caroline Grygar, Manon Marcu, Frédéric Triebel

Mendeley readers

The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 <1%
United States 1 <1%
Canada 1 <1%
Australia 1 <1%
Unknown 112 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 28 24%
Student > Ph. D. Student 22 19%
Other 11 9%
Student > Bachelor 10 9%
Student > Doctoral Student 8 7%
Other 16 14%
Unknown 21 18%
Readers by discipline Count As %
Medicine and Dentistry 24 21%
Immunology and Microbiology 21 18%
Agricultural and Biological Sciences 21 18%
Biochemistry, Genetics and Molecular Biology 15 13%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 8 7%
Unknown 23 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2022.
All research outputs
#1,860,034
of 22,557,763 outputs
Outputs from Clinical Cancer Research
#1,468
of 12,539 outputs
Outputs of similar age
#5,350
of 79,427 outputs
Outputs of similar age from Clinical Cancer Research
#7
of 101 outputs
Altmetric has tracked 22,557,763 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,539 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 79,427 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.